Novartis, Paratek in deal to develop MRSA drug

10/8/2009 | Reuters

Novartis acquired exclusive global rights to PTK 0796, Paratek Pharmaceuticals' treatment for methicillin-resistant Staphylococcus aureus and other drug-resistant bacteria. The drug is in Phase III trials and has shown promise in safety and tolerability.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD